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Tubuloglomerular feedback: New concepts and developments.
Luminal [NaCl] at the macula densa (MD) has two established
effects: regulation of glomerular arteriolar resistance through
tubuloglomerular feedback (TGF) and control of renin secretion.
TGF acts as a minute-to-minute stabilizer of distal salt delivery,
thereby minimizing the impact of random perturbations in filtra-
tion and absorption forces on NaCl excretion. During long-lasting
perturbations of MD [NaCl], control of renin secretion becomes
the dominant function of the MD. The potentially maladaptive
effect of TGF under chronic conditions is prevented by TGF
adaptations permitting adjustments in glomerular filtration rate to
occur. TGF adaptation is mechanistically coupled to the endpoint
targeted by chronic deviations in MD [NaCl], the rate of local and
systemic angiotensin II generation. Studies of TGF in transgenic
mice are expected to provide further insights into the mechanisms
mediating between luminal [NaCl] and afferent arterioles. TGF
responses are virtually abolished in mice in which either the AT1A
gene or the angiotensin converting enzyme gene is rendered
nonfunctional by homologous recombination. In contrast, TGF
responses are unaltered in nitric oxide synthase I knockout mice.
Thus, an intact renin-angiotensin system appears to be critical for
the TGF signaling pathway.
CONCEPT OF TUBULOGLOMERULAR FEEDBACK
The vascular response
Goormaghtigh, Harsing, and Thurau clearly recognized
that the existence of a tubulovascular connection at the site
of the macula densa (MD) provides an ideal pathway along
which changes in the composition of the urine at that point
can affect afferent arteriolar tone and thereby glomerular
filtration rate (GFR) [1–3]. The site of the MD is particu-
larly suited for the location of a chemoreceptor because
[NaCl] at this site is hypotonic, variable, and determined
almost exclusively by loop of Henle flow rate. Beginning
with Thurau’s microinjection experiments, numerous inves-
tigators have now established firmly that GFR is in fact
inversely related to [NaCl] at the MD [4]. The vascular
response to a change in [NaCl] occurs over a limited range
of concentrations extending, in the hydropenic rat, from
about 15 to 60 mM [5]. The response is nonlinear with
sensitivity greatest in the range of ambient [NaCl], about 20
to 30 mM in the hydropenic rat. Because an increase in
[NaCl] decreases single nephron GFR (SNGFR), the rela-
tionship between epithelial and vascular cells represents a
negative feedback loop, usually called the tubuloglomeru-
lar feedback (TGF) mechanism.
The renin secretory response
It is now clear that changing MD [NaCl] has a second
effect: it regulates the secretion of renin from the granular
cells of the juxtaglomerular apparatus (JGA) and thereby is
a determinant of extracellular angiotensin II (Ang II)
concentrations. As originally suggested by Vander, a de-
crease in MD [NaCl] stimulates, and an increase inhibits
renin secretion [6]. This response, like the TGF response,
has been shown in vitro to occur over the range of about 10
to 60 mM. The difference between minimal and maximal
rates of secretion in this preparation is large, about sixfold
[7]. Concurrent operation of the two MD-dependent mech-
anisms might be predicted to generate two rigidly coupled
functional triads: states of high MD [NaCl] associated with
vasoconstriction and an inhibited renin-angiotensin system
(RAS) or, conversely, states of low MD [NaCl] combined
with vasodilatation and activation of the RAS, yet these
triads are almost never observed. In all states of volume
depletion, for example, MD [NaCl] and transport are
almost certainly decreased, but these are states of vasocon-
striction, not vasodilatation. It is likely that this paradox can
be resolved by the very different temporal characteristics of
the two responses.
Co-ordination of vascular and renin secretory responses
The TGF response, which takes about 10 seconds to
become maximal, is the faster by far of the two responses.
The renin secretory response in the single perfused JGA
increases over 5 to 15 minutes; in the whole animal, the
time course is not quite clear. Maximal changes in plasma
levels of Ang II produced by a persistently changed MD
[NaCl] probably require 30 to 60 minutes. These temporal
characteristics make it likely that TGF contributes substan-
tially to the control of afferent arteriolar tone when distal
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[NaCl] is changed by rapid and randomly oscillating factors.
Such factors may impact on GFR without being related to
body salt balance. An example would be step changes in
arterial pressure, changes that, in the physiological context,
are typified by the random and fast changes in blood
pressure found during long-term pressure recordings [8].
These random fluctuations in MD NaCl probably are
dampened effectively by operation of TGF but, given their
high frequency, do not cause changes in renin secretion,
and certainly not systemic plasma renin and Ang II levels
(Fig. 1).
On the other hand, renin secretion and extracellular Ang
II levels will change when MD [NaCl] is dislodged from its
set point for a prolonged time. This will occur when the
combined external forces determining GFR and proximal
and loop absorption cause deflections of MD [NaCl] that
exceed the range of flows over which TGF operates effec-
tively. Deflections of MD [NaCl] will then inevitably
change both renin secretion and extracellular [Ang II]. The
time frame within which MD [NaCl] may be expected to
produce this effect is not quite certain but can be estimated
to be in the order of 30 to 60 minutes. Thus, tight control
of distal NaCl delivery by TGF is the function of the JGA
only in the short term. In the long term, the JGA is
primarily responsible for the secretion of renin at a rate
that is optimal for the maintenance of Na balance.
It is important to realize (Fig. 1) that the TGF system in
the new steady state, after MD [NaCl] and renin secretion
have changed, does not remain inoperative but regains
homeostatic efficiency by the phenomenon of resetting, an
observation anticipated and first made by Thurau [4, 9]. In
volume expansion, for example, inhibition of proximal or
loop of Henle transport causes MD [NaCl] and transport to
increase. This change, when it persists, causes renin secre-
tion to decrease but also causes TGF to adapt in the sense
that it becomes less sensitive. Thus, when [NaCl] at the MD
is increased for a prolonged time, the decrease in GFR
predicted from the acute TGF function does not occur.
Rather, steady-state GFR stays the same or may even
increase. The advantage is twofold: adaptation keeps TGF
in the regulatory range so that it can continue to function as
a fast controller, and it prevents changes in GFR when
these would be maladaptive.
The mechanism of resetting is presumably multifactorial,
but the most important single factor is extracellular Ang II,
with increasing Ang II causing a left shift and decreasing
Ang II causing a right shift of the TGF function curve.
Because Ang II is controlled by chronic changes in MD
NaCl, the phenomena of MD-controlled renin secretion
and TGF resetting are mechanistically coupled. The mech-
anism by which Ang II affects the TGF function curve is
presumably a reflection of its specific interaction with
adenosine, which is an important mediator of the TGF
response.
Should the TGF system, in fact, act only as a fast control
system, its regulatory importance under chronic conditions
may have to be reconsidered. When it is observed experi-
mentally that MD [NaCl] is increased or decreased, and
one may assume that this change has persisted for some
time, it would seem a priori unlikely that TGF has been
responsible for any inverse changes in GFR that may be
found at the same time. For example, an increased MD
[NaCl] following prolonged inhibition of proximal trans-
port (as occurs with a carbonic anhydrase blocker) would
be unlikely to be the cause of the observed fall of GFR. It
is more likely that the predicted fall of renin secretion in
this condition (provided volume depletion is prevented), or
some other consequence of increased distal flow, will cause
TGF adaptation, thereby preventing a decrease of GFR. If
GFR decreases anyway, this is probably due to some other,
non—JGA-related causes. Furthermore, observing that the
TGF function, as reflected in the relationship between late
proximal flow (VLP) or MD [NaCl] and SNGFR, is altered
or reset, the conclusion that the change in the TGF
function is a primary event permitting MD [NaCl], and with
it GFR, to change may not be justified. For example, the
desensitization of TGF in volume expansion has been
assumed to be causal in the elevated GFR often found in
this condition. However, it may be more likely that the
relationship is just the reverse, that is, that a change in
Fig. 1. Function of the juxtaglomerular
apparatus (JGA). (A) Short-term function.
With random high-frequency perturbations,
macula densa (MD) [NaCl] and glomerular
filtration rate (GFR) oscillate around a set
point, whereas plasma renin does not change.
(B) Long-term function of the JGA. With
prolonged perturbations exceeding the
operating range of the tubuloglomerular
feedback (TGF) mechanism, plasma renin
changes concomitantly with resetting of the
TGF function curve. Resetting permits
stabilization of MD [NaCl] and GFR at a new
operating point.
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[NaCl] at the MD elicited by factors extrinsic to the JGA
causes the feedback function to adapt or reset. This notion
has recently also been expressed by Thomson et al, and we
fully share their sentiment that “TGF resetting is more
likely a result, rather than a cause, of any sustained increase
in (SN)GFR” [10].
NEW DEVELOPMENTS IN TGF REGULATION
Transgenic mice as experimental models
The problem of the identity of humoral or other factors
participating in mediation of the NaCl-induced vasomotor
response has been difficult to study. Progress in this area
has depended largely on studies of the effect of pharmaco-
logical interventions designed to interfere with the opera-
tion of potential mediator pathways. Despite the important
insights yielded by the administration of exogenous ago-
nists and antagonists, the validity of conclusions reached
depends on assumptions that cannot always be proven,
particularly not in complex in vivo studies. In general,
neither the specificity of the pharmacological agent used
nor the completeness of blockade can be definitively estab-
lished, mainly because the concentration at the site of
action is usually unknown. Furthermore, experimental ap-
proaches may be too demanding to permit the construction
of full dose-response relationships, and conclusions are
often based on the use of single drug doses.
Advances in transgenic and gene-targeting approaches
provide alternative or complementary approaches to study-
ing complex cell-cell signaling pathways. Random insertion
of gene constructs by either retroviral gene delivery or
injection of pronuclei has generated animals, usually mice,
that overexpress certain genes and are therefore an alter-
native method to minipump or other chronic infusion
studies for examining the long-term effect of endogenous
bioactive agents [11, 12]. Homologous recombination, in
contrast, has permitted the generation of transgenic mice
with targeted deletions of specific genes [13, 14]. Thus,
these animals can be used as the genetic equivalent of
pharmacological blocker or surgical ablation studies. De-
finitive, and often unexpected, information on the develop-
mental contributions of certain genes has been obtained.
These animals also offer a new and independent means of
addressing some of the questions that have been studied
previously with pharmacological tools, and they are, there-
fore, increasingly used in studies of the effect of gene
deletions on specific tissue and organ functions.
The use of gene-knockout models offers the unique
advantage that, with an optimal targeting construct, a gene
product of interest simply is not expressed in the animal;
thus, a change in function implies a direct or indirect role of
this gene in the phenomenon under study. On the other
hand, if no effect is seen, one may conclude either that the
targeted gene is of no, or only minor, importance in the
studied system or that compensatory mechanisms have
been up-regulated to take the place of the deleted product.
Studies of such compensatory mechanisms acting in mice
with null mutations would seem to be promising in their
own right. When the gene deletion is lethal either before or
shortly after birth, the use of transgenic mice is limited to
heterozygous animals [15]. In general, expression of the
targeted gene in heterozygotes is intermediate between the
normal and the homozygous mutant animal, and the
change in the level of the gene product may be sufficiently
large to cause detectable functional alterations. Functional
approaches in null mutant animals may also be problematic
if the gene deletion causes severe structural alterations in
the organ under study [16].
Studies of renal function in mice
Due no doubt to the size of the animal, about one tenth
of that of a laboratory rat, measurements of baseline
physiological parameters in the mouse are not abundant
but are needed to permit comparison with animals carrying
single gene mutations. The acquisition of a wide array of
such data will certainly require miniaturization of existing
methods, a process that is hoped to be driven eventually by
increasing demand. However, in some instances, methods
that have been used for studies in rats can be directly
transferred to mouse studies.
We have explored the feasibility of utilizing standard
micropuncture techniques for studying nephron function in
both normal and transgenic mice and have found that this
approach is applicable to mice with relatively minor mod-
ifications [17]. A combination of thiobutabarbital (100
mg/kg i.p.) and ketamine (50 mg/kg i.m.) reliably induces a
controllable level of anesthesia. Not surprisingly, prepara-
tion of mice for renal micropuncture is substantially more
time consuming than in rats, mainly due to more difficult
blood vessel cannulation requiring exceptional care and
patience. Cannulation of the femoral vein and artery with
fine, hand-drawn polyethylene catheters is felt to be the
best method of vascular access for infusion (2.25 g% bovine
serum albumin in saline at 0.5 ml/hr) and blood pressure
(BP) measurement. Although it is possible to cannulate the
ureter close to the kidney, we have found that these
catheters have a tendency to obstruct with small urinary
crystals so that urine is collected usually with a bladder
catheter.
Baseline renal function in C57BL/6 mice (body wt 30 to
40 g) is summarized in Table 1. Mean arterial BP (MAP) in
13 anesthetized and laparatomized animals was 87 6 6 mm
Hg. Mean renal blood flow determined with a Transonic
Systems ultrasonic flowmeter and a 0.5-mm V-series probe
averaged 1.1 ml/min per kidney (N 5 9). GFR determined
as 125Iothalamate clearance was 0.18 6 0.02 ml/min/kidney.
Nephron number, determined as the average of 20 glomer-
ular counts in aliquots of macerated kidney suspensions,
was 13,769 6 1,028. SNGFR determined with 125Iothala-
mate (bolus injection of 0.5 mC/100 g followed by an
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infusion of 10 mC/100 g/h) was 15.8 6 0.83 nl/min when
measured by complete collection from the late proximal
tubule and 13.7 6 0.64 when determined by quantitative
collections in the distal tubule. The difference (2.07 6 0.52
nl/min) is significant (P , 0.02) in these paired measure-
ments. Based on these measurements, normal late proximal
flow rate can be estimated to be 6 to 8 nl/min, values in
agreement with earlier work [18].
Using the open-loop microperfusion approach, TGF
responses of stop-flow pressure (PSF) and SNGFR were
determined in five mice. Mean PSF at zero loop flow was
36.9 6 2.2 mm Hg falling to 33.8 6 1.5 mm Hg at 5 nl/min
and to 31.5 1.3 mm Hg at 10 nl/min. Responses were
saturated by flows greater than 25 nl/min, with the maxi-
mum PSF decrease averaging 12.5 6 1.4 mm Hg. The flow
producing a half-maximum response (V1/2) was 9 6 1.2 mm
Hg. Thus, commensurate with lower ambient flow rates, the
TGF function is shifted to the left compared with the rat.
As a consequence, as in the rat, steady-state SNGFR is
situated in the most sensitive region of the TGF curve. Like
PSF, SNGFR decreases with increasing loop flow, and this
decrease also occurs for the most part at flows less than 15
nl/min. TGF responses were attenuated in mice infused
with 2.4 ml/h isotonic saline, an expansion of extracellular
volume causing urine flow to increase from 1.5 to 8 l/min,
and urine osmolarity to fall from 1050 to 365 liter/min. In
these volume-expanded mice, increasing loop perfusion
rate from 0 to 40 nl/min caused PSF to decrease by only 3
mm Hg, from 40.4 6 0.9 mm Hg to 37.4 6 0.8 mm Hg.
Studies of JGA function in transgenic mice
Angiotensin 1A-receptor (AT1A)-knockout mice. Studies
were undertaken in AT1A receptor-knockout mice using
the strain generated by Ito et al [19]. Mean body weights
and mean kidney weights were not different between
wild-type, heterozygous, and homozygous animals (BW:
27.2 6 1.2, 26.5 6 0.65, and 26.4 6 1.3 g, respectively).
MAP was 91.8 6 2.2 mm Hg in wild type (range 83.5 to 96)
and 97.2 6 3 mm Hg in heterozygotes (91-104). MAP in
homozygotes was significantly lower, with a mean of 80.7 6
3.2 mm Hg (range 71.5 to 91; P 5 0.045 vs. AT1A 1/1, P 5
0.007 vs. AT1A 1/2). BP responses to exogenous Ang II
were similar in AT1A 1/1 and AT1A 1/2 mice but were
markedly blunted in AT1A 2/2 animals. In addition to
polymerase chain reaction genotyping, this difference in
the BP response to Ang II was used as independent
corroboration of complete AT1A receptor null mutation. In
wild-type littermates, mean PSF at zero flow was 37.2 6 1.6
mm Hg. Increments in loop flow caused a decrease in PSF
with a V1/2 of 8.7 6 0.4 nl/min. Minimum PSF (about 29 mm
Hg) was established at 15 nl/min. In AT1A 1/2 mice, PSF at
zero flow was 39.9 6 2.4 mm Hg, falling to 35.7 6 2.4 mm
Hg at 15 nl/min. V1/2 was similar to that in normal mice,
8.6 6 1 nl/min. In contrast, in AT1A 2/2 mice, PSF did not
change significantly with increases in loop perfusion rate.
Overall, PSF fell by a maximum of about 9 mm Hg in AT1A
1/1, 5.1 6 0.4 mm Hg in AT1A 1/2 and only 0.64 6 0.3
mm Hg in AT1A 2/2 animals (Fig. 2).
Angiotensin converting enzyme (ACE)-knockout mice.
Experiments were performed on mice from a colony of the
ACE mutants generated by Krege et al [20]. MAP in four
wild-type mice of this strain prepared for micropuncture
was 94.4 6 2.65 mm Hg and 85.9 6 1.6 and 85.5 6 4.2 mm
Hg in five ACE 1/2 and two ACE 2/2 mice. BP responses
to angiotensin I (Ang I) were greatly attenuated in the
ACE 2/2 mice, whereas BP responses to Ang II were not
significantly different between the three groups of mice.
These results are similar to a recent report by Tian et al
[21].
As in the AT mutants, TGF responses were severely
blunted in the ACE-knockout animals. In ACE 1/1 mice,
PSF fell by 9.2 6 0.9 mm Hg, from 42.1 6 1.3 to 32.9 6 1.55
mm Hg (N 5 16) on increasing loop perfusion rate from 0
to 40 nl/min. In ACE 2/2 null mutants, PSF was 39.5 6 1.7
mm Hg at zero loop flow and 39.3 6 1.6 mm Hg at 40
nl/min (NS; N 5 10). Interestingly, TGF responses were
also blunted in ACE 1/2 mice, with PSF falling from
41.2 6 2.5 to 38.9 6 2.29 mm Hg (N 5 12). The mean
decrease (2.25 6 0.5 mm Hg) was significantly lower than in
ACE 1/1 animals (Fig. 2). Ang II infused at 100 ng/kg per
min, a rate that does not increase MAP significantly in
these mice, partly restored TGF responsiveness.
Nitric oxide synthase I (NOS I)-knockout mice. Anesthe-
tized and laparatomized mice with a null mutation in the
NOS I gene [22] had a MAP of 99.6 6 1.7 (N 5 7) versus
96.6 6 3.8 mm Hg in NOS I 1/1 animals (N 5 6). TGF
responses of PSF to changes in loop perfusion rate were not
different between wild type and NOS I 2/2. In NOS I 1/1
mice (13 tubules), mean PSF at zero loop flow was 40.3 6
1.8 mm Hg and 31.9 6 1.8 mm Hg at 45 nl/min (8.5 6 0.7
mm Hg). V1/2 was about 12 nl/min. In NOS I 2/2 animals
Table 1. Renal and nephron function in anesthetized and
laparatomized mice of the C57BL/6 strain
Parameter means 6SEM N
Body weight g 27.2 6 1.9 10
Kidney weight mg 170.5 6 9.1 10
MABP mm Hg 87 6 6 13
Nephron number/kidney 13769 6 1028 3
Mean RBF ml/min/kidney 1.1 6 0.11 9
GFR ml/min/kidney 0.18 6 0.02 5
SNGFRLP nl/min 15.8 6 0.83 5
SNGFRD nl/min 13.7 6 0.64 5
PSF-0 mm Hg 36.9 6 2.2 5
PSF-40 mm Hg 24.2 6 2.01 5
D PSFmax mm Hg 12.4 6 1.4 5
V1/2 nl/min 8.9 6 1.1 5
Abbreviations are: MABP, mean arterial blood pressure; RBF, renal
blood flow; GFR, glomerular filtration rate; SNGFR, single nephron
GFR; LP, D late proximal, distal, respectively; PSF, stop-flow pressure (0,
40 loop perfusion rates in nl/min); PSFmax maximum change in PSF, V1/2
loop perfusion rate for half-maximal response.
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(18 tubules), mean PSF at zero flow was 40.7 6 1.7 mm Hg,
with a steady-state value of 31.9 6 2 mm Hg at 45 nl/min
(9.1 6 0.7 mm Hg). V1/2 was about 13 nl/min. Acute NOS
inhibition augments TGF responsiveness, a finding suggest-
ing a modifying effect of MD-derived NO in juxtaglomer-
ular signal transmission [23, 24]. In contrast, the current
observations show that chronic and selective absence of NO
generated by NOS I in MD cells is not associated with
augmented TGF responses (Fig. 2).
Expression of renin, determined by in situ hybridization,
was reduced in NOS I 2/2 mice, with only 34% of vascular
poles showing a renin signal (56% in control). These results
coincide with a recent study reporting a renal renin content
about 50% lower in NOS I 2/2 mice compared with mice
of the two progenitor strains [25]. It is possible therefore
that reduced local activity of the RAS in NOS I-deficient
mice may compensate for TGF enhancement in NO defi-
ciency. A recent study by Brenman et al has revealed the
existence of a shorter isoform of NOS I mRNA in which the
second exon is spliced out [26]. Because the second exon
was targeted as the site of the gene disruption, this short
isoform may be expressed in the NOS I-knockout mice and
is in fact found at a low level in the brain of these animals
[26]. Its presence in MD cells and the functional impor-
tance of any remaining NOS activity in these cells are
currently unknown.
SUMMARY AND PERSPECTIVES
TGF acts as a minute-to-minute stabilizer of distal salt
delivery and is therefore an important mechanism control-
ling NaCl excretion during fast and random perturbations
in filtration and absorption forces that are unrelated to
body salt balance. Changes in distal salt delivery too large
to be fully compensated by TGF, and therefore persisting
for a prolonged time, are followed by changes in renin
secretion and extracellular [Ang II], the second effect
initiated by a change in MD [NaCl]. One consequence of
this change in Ang II availability is adaptation or resetting
of the TGF system. Restoration of TGF responsiveness at
a different operating point permits the TGF mechanism to
continue to function as a high frequency regulator of salt
excretion.
JGA studies in genetically modified animals have con-
firmed that RAS integrity is critical for the operation of
TGF. The response-modifying effect of Ang II appears to
be mediated exclusively by AT1A angiotensin receptors. In
contrast, the presence of NOS I in MD cells, and therefore
presumably of NO released by these cells, does not appear
to be an important modulator under chronic conditions.
Initial studies using an isolated perfused JGA preparation
confirm, however, that the presence of NOS I is necessary
for NaCl-dependent renin secretion.
The use of genetically altered mice already offers unique
opportunities for studying regulatory problems that have
been difficult to answer unequivocally. It is to be expected
that advances in gene modification techniques and in the
physiological methodology applicable to mice will augment
the experimental options further. Chimeric mice with re-
gional gene deletions may provide an opportunity for
comparing cellular functions between mutated and normal
cells in the same animal [27]. Gene duplication will com-
plement null mutations by permitting comparisons of the
functional effect of a gene over a fourfold range in the
number of gene copies [28]. The generation of double
knockout animals by interbreeding will expand the analysis
of the consequences of gene deletions and maybe particu-
larly useful for the analysis of compensatory mechanisms.
The use of tetracycline-responsive targeting constructs may
provide temporal control over gene activation as well as
inactivation [29]. Finally, tissue-specific gene inactivation
may become feasible by the use of Cre-mediated homolo-
gous recombination [30, 31]. In summary, the combination
of genetic manipulation with detailed and precise physio-
logical analysis is expected to provide an array of ap-
proaches with almost unlimited potential for improving our
understanding of integrated body functions.
Fig. 2. Maximum change in stop-flow pressure (response to a loop of
Henle flow change from 0 to 40 nl/min) in heterozygous and homozygous
AT1A angiotensin receptor, angiotensin converting enzyme (ACE), and
nitric oxide synthase (NOS)-I knockout mice, and in wild type littermates.
NOS-I heterozygotes were not studied. Vertical bars are SEM. Symbols are:
(M) wild-type 1/1; (o) heterozygous 1/2; (z) homozygous 2/2.
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